Johnson & Johnson is a defensive pick with a renewed focus on its pharmaceutical and medtech segments. The recent selloff in the stock has brought its valuation down to undervalued levels. Johnson ...

Until recently Johnson & Johnson (NYSE: JNJ ) stock was the most conservative investment you could make in the drugs space. It still is, but that's no longer a compliment.

Johnson & Johnson (NYSE:JNJ) is slated to report earnings before the market opens on Tuesday in what will be the company's first report since spinning off its consumer health division, Kenvue.  For...

Stocks have turned volatile in response to rising bond yields. High-quality dividend stocks could be a great way to ride out this rough patch.

Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positi...

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Johnson & Johnson (NYSE: JNJ) is trading just above its year-to-date low at writing – which creates an opportunity to invest in a quality name at a discount, as per an RBC Capital Markets analyst. ...

The healthcare industry is full of manual processes that could benefit from AI. AI can help improve outcomes for patients while also growing revenue for businesses.

Coca-Cola and J&J both have long track records of increasing dividend payments to shareholders. These companies also offer bright earnings prospects well into the future, thanks to their solid prod...

The Dow Jones Industrial Average is home to 30 generally profitable, diverse, multinational businesses. A pullback in the Dow from its 2023 high is the perfect opportunity for long-term investors t...

A New Jersey appeals court on Tuesday threw out a $223.8 million verdict against Johnson & Johnson in a trial over four plaintiffs' claims that they developed cancer from being exposed to the compa...

J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.

J&J recently spun off its billion-dollar consumer health business to form Kenvue. Kenvue announced a dividend during its first earnings report as an independent entity.

In the new century, economic uncertainty often looms. Finding investment opportunities that can weather the storm is a quest every investor undertakes.